4//SEC Filing
Rabinowitz Michael 4
Accession 0001213900-21-040761
CIK 0001176309other
Filed
Aug 5, 8:00 PM ET
Accepted
Aug 6, 4:01 PM ET
Size
8.0 KB
Accession
0001213900-21-040761
Insider Transaction Report
Form 4
Rabinowitz Michael
Chief Commercial Officer
Transactions
- Award
Common Stock
2021-08-04+100,000→ 100,000 total - Award
Stock Option (right to buy)
2021-08-04+100,000→ 100,000 totalExercise: $15.10Exp: 2031-08-04→ Common Stock (100,000 underlying)
Footnotes (3)
- [F1]Represents common stock underlying Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The RSUs will vest as follows: 33,333 shall vest if the closing price per share of the Issuer's common stock will be $15 for at least 20 days, 33,333 shall vest if the closing price per share of the Issuer's common stock will be $25 for at least 20 days, and 33,334 shall vest if the Issuer consummates an arm's length licensing or other strategic transaction, that includes its phase 3 oral insulin product, for no less than $50,000,000 in upfront cash (including proceeds from any upfront stock equity purchase).
- [F3]The Stock Options will vest in five installments as follows: 12,500 shall vest on December 31, 2021, 25,000 shall vest on each of December 31, 2022, December 31, 2023 and December 31, 2024, and 12,500 shall vest on August 4, 2025.
Documents
Issuer
ORAMED PHARMACEUTICALS INC.
CIK 0001176309
Entity typeother
Related Parties
1- filerCIK 0001767090
Filing Metadata
- Form type
- 4
- Filed
- Aug 5, 8:00 PM ET
- Accepted
- Aug 6, 4:01 PM ET
- Size
- 8.0 KB